In a report released yesterday, John Newman from Canaccord Genuity maintained a Buy rating on Marker Therapeutics, with a price target of $8.00.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
John Newman’s rating is based on several promising developments for Marker Therapeutics. The company anticipates a significant data update for their MT-601 therapy in the latter half of 2025, which is expected to include a larger patient sample. This therapy targets relapsed lymphoma patients using a unique multi-antigen approach, setting it apart from existing CD19 CAR-T therapies.
Marker Therapeutics sees a substantial commercial opportunity in the lymphoma market, estimating around 8,000 patients globally by 2024, with a significant portion experiencing relapse. The potential market size is projected to be approximately $1.7 billion. The company’s financial position, with $13.7 million in cash reported in the first quarter of 2025, supports their ongoing research and development efforts, justifying the Buy rating and an $8 price target.
MRKR’s price has also changed moderately for the past six months – from $1.590 to $1.280, which is a -19.50% drop .